Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (102) 102
life sciences & biomedicine (97) 97
humans (93) 93
oncology (73) 73
female (72) 72
male (64) 64
middle aged (59) 59
aged (52) 52
adult (42) 42
tumors (35) 35
human necessities (32) 32
hygiene (32) 32
medical or veterinary science (32) 32
preparations for medical, dental, or toilet purposes (32) 32
aged, 80 and over (29) 29
biological and medical sciences (29) 29
medical sciences (27) 27
mutation (25) 25
treatment outcome (25) 25
cancer (22) 22
care and treatment (22) 22
abridged index medicus (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
specific therapeutic activity of chemical compounds ormedicinal preparations (16) 16
prognosis (15) 15
research (15) 15
retrospective studies (15) 15
neoplasm staging (14) 14
antineoplastic agents (13) 13
protein kinase inhibitors - therapeutic use (13) 13
surgery (13) 13
animals (12) 12
analysis (11) 11
antineoplastic agents - therapeutic use (11) 11
chemotherapy (11) 11
gastroenterology. liver. pancreas. abdomen (11) 11
mice (11) 11
neoplasms - drug therapy (11) 11
pancreatic cancer (11) 11
pancreatic neoplasms - pathology (11) 11
radiotherapy (11) 11
adenocarcinoma - pathology (10) 10
deoxycytidine - analogs & derivatives (10) 10
gene amplification (10) 10
health aspects (10) 10
hematology, oncology and palliative medicine (10) 10
lung neoplasms - drug therapy (10) 10
pancreatic neoplasms - drug therapy (10) 10
patients (10) 10
pyrazoles - therapeutic use (10) 10
pyridines - therapeutic use (10) 10
survival rate (10) 10
adenocarcinoma - therapy (9) 9
carcinoma, non-small-cell lung - drug therapy (9) 9
fluorouracil - administration & dosage (9) 9
liver. biliary tract. portal circulation. exocrine pancreas (9) 9
medicine & public health (9) 9
multiple tumors. solid tumors. tumors in childhood (9) 9
neoadjuvant therapy (9) 9
pharmacology. drug treatments (9) 9
adenocarcinoma - genetics (8) 8
adenocarcinoma - mortality (8) 8
colorectal cancer (8) 8
colorectal neoplasms - drug therapy (8) 8
disease-free survival (8) 8
general & internal medicine (8) 8
lung neoplasms - genetics (8) 8
medicine, general & internal (8) 8
pancreatic neoplasms - mortality (8) 8
carcinoma, non-small-cell lung - genetics (7) 7
colorectal neoplasms - genetics (7) 7
dose-response relationship, drug (7) 7
follow-up studies (7) 7
genetic aspects (7) 7
neoplasms (7) 7
nuclear radiation (7) 7
original reports (7) 7
pancreatic neoplasms - radiotherapy (7) 7
pancreatic neoplasms - therapy (7) 7
proto-oncogene proteins c-met - genetics (7) 7
receptor, epidermal growth factor - genetics (7) 7
stomach cancer (7) 7
survival (7) 7
young adult (7) 7
adenocarcinoma - drug therapy (6) 6
adenocarcinoma - surgery (6) 6
biopsy (6) 6
capecitabine (6) 6
cell biology (6) 6
chemoradiotherapy (6) 6
combined modality therapy (6) 6
deoxycytidine - administration & dosage (6) 6
fluorouracil - analogs & derivatives (6) 6
genotype (6) 6
kaplan-meier estimate (6) 6
liver neoplasms - secondary (6) 6
maximum tolerated dose (6) 6
metastasis (6) 6
neoplasms - metabolism (6) 6
neoplasms - pathology (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (195) 195
French (7) 7
Chinese (4) 4
German (4) 4
Korean (2) 2
Portuguese (2) 2
Danish (1) 1
Greek (1) 1
Norwegian (1) 1
Polish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study
by Camidge, D Ross, Dr and Bang, Yung-Jue, Prof and Kwak, Eunice L, MD and Iafrate, A John, MD and Varella-Garcia, Marileila, Prof and Fox, Stephen B, Prof and Riely, Gregory J, MD and Solomon, Benjamin, MBBS and Ou, Sai-Hong I, MD and Kim, Dong-Wan, Prof and Salgia, Ravi, Prof and Fidias, Panagiotis, MD and Engelman, Jeffrey A, MD and Gandhi, Leena, MD and Jänne, Pasi A, MD and Costa, Daniel B, MD and Shapiro, Geoffrey I, MD and LoRusso, Patricia, DO and Ruffner, Katherine, MD and Stephenson, Patricia, ScD and Tang, Yiyun, PhD and Wilner, Keith, PhD and Clark, Jeffrey W, MD and Shaw, Alice T, MD
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - enzymology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Pyridines - adverse effects | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Pyrazoles - adverse effects | Pyridines - therapeutic use | Care and treatment | Safety and security measures | Genes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
by Shaw, Alice T, Dr and Yeap, Beow Y, ScD and Solomon, Benjamin J, MD and Riely, Gregory J, MD and Gainor, Justin, MD and Engelman, Jeffrey A, MD and Shapiro, Geoffrey I, MD and Costa, Daniel B, MD and Ou, Sai-Hong I, MD and Butaney, Mohit, BS and Salgia, Ravi, Prof and Maki, Robert G, MD and Varella-Garcia, Marileila, Prof and Doebele, Robert C, MD and Bang, Yung-Jue, Prof and Kulig, Kimary, PhD and Selaru, Paulina, MSPH and Tang, Yiyun, PhD and Wilner, Keith D, PhD and Kwak, Eunice L, MD and Clark, Jeffrey W, MD and Iafrate, A John, MD and Camidge, D Ross, MD
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Patient Selection | Multicenter Studies as Topic | Time Factors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Retrospective Studies | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Risk Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Australia | Clinical Trials, Phase I as Topic | Care and treatment | Analysis | Patient outcomes | Genetic research | Genetic aspects | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
by Tap, William D and Wainberg, Zev A and Anthony, Stephen P and Ibrahim, Prabha N and Zhang, Chao and Zhang, Jiazhong and Zhang, Ying and Healey, John H and Chmielowski, Bartosz and Staddon, Arthur P and Cohn, Allen Lee and Shapiro, Geoffrey I and Keedy, Vicki L and Singh, Arun S and Puzanov, Igor and Kwak, Eunice L and Wagner, Andrew J and Von Hoff, Daniel D and Weiss, Glen J and Ramanathan, Ramesh K and Habets, Gaston and Burton, Elizabeth A and Visor, Gary and Sanftner, Laura and Severson, Paul and Nguyen, Hoa and Kim, Marie J and Marimuthu, Adhirai and Tsang, Garson and Shellooe, Rafe and Gee, Carolyn and West, Brian L and Hirth, Peter and Nolop, Keith and van de Rijn, Matt and Hsu, Henry H and Peterfy, Charles and Lin, Paul S and Tong-Starksen, Sandra and Bollag, Gideon
The New England journal of medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 5, pp. 428 - 437
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Aminopyridines - administration & dosage | Receptor, Macrophage Colony-Stimulating Factor - antagonists & inhibitors | Pyrroles - pharmacokinetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Aminopyridines - adverse effects | Giant Cell Tumors - pathology | Soft Tissue Neoplasms - drug therapy | Crystallography, X-Ray | Male | Tumor Burden | Drug Discovery | Receptor, Macrophage Colony-Stimulating Factor - metabolism | Dose-Response Relationship, Drug | Giant Cell Tumors - drug therapy | Pyrroles - administration & dosage | Tendons - pathology | Soft Tissue Neoplasms - pathology | Pyrroles - adverse effects | Adult | Female | Aged | Treatment outcome | Colony-stimulating factors (Physiology) | Care and treatment | Dosage and administration | Giant cell tumors | Analysis | Edema | Genes | Macrophage colony-stimulating factor | Fatigue | Nausea | Kinases | Crystallography | Patients | Colony-stimulating factor | Drug discovery | Solid tumors | Drug therapy | Conformation | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
by Kwak, Eunice L
The New England journal of medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 6, pp. 588 - 588
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
by Dias‐Santagata, Dora and Akhavanfard, Sara and David, Serena S and Vernovsky, Kathy and Kuhlmann, Georgiana and Boisvert, Susan L and Stubbs, Hannah and McDermott, Ultan and Settleman, Jeffrey and Kwak, Eunice L and Clark, Jeffrey W and Isakoff, Steven J and Sequist, Lecia V and Engelman, Jeffrey A and Lynch, Thomas J and Haber, Daniel A and Louis, David N and Ellisen, Leif W and Borger, Darrell R and Iafrate, A. John
EMBO molecular medicine, ISSN 1757-4676, 05/2010, Volume 2, Issue 5, pp. 146 - 158
cancer | profiling | targeted therapies | genotyping | Targeted therapies | Profiling | Genotyping | Cancer | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Clinical Laboratory Techniques - methods | Neoplasms - therapy | Neoplasms - genetics | Humans | Genotype | Mutation | DNA Mutational Analysis - methods | Precision Medicine - methods | Polymerase Chain Reaction - methods | Medical research | Laboratories | Genes | Embedding | Histology | Genomes | Phosphatase | Paraffin | Kinases | Patients | Cancer therapies | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Isolation of rare circulating tumour cells in cancer patients by microchip technology
by Nagrath, Sunitha and Sequist, Lecia V and Maheswaran, Shyamala and Bell, Daphne W and Irimia, Daniel and Ulkus, Lindsey and Smith, Matthew R and Kwak, Eunice L and Digumarthy, Subba and Muzikansky, Alona and Ryan, Paula and Balis, Ulysses J and Tompkins, Ronald G and Haber, Daniel A and Toner, Mehmet
Nature (London), ISSN 0028-0836, 12/2007, Volume 450, Issue 7173, pp. 1235 - 1239
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Microarray Analysis - methods | Neoplastic Cells, Circulating - pathology | Microarray Analysis - instrumentation | Humans | Male | Neoplasms - diagnosis | Cell Separation - methods | Neoplasms - drug therapy | Microfluidics - instrumentation | Neoplasm Metastasis | Neoplasms - blood | Sensitivity and Specificity | Female | Neoplasms - pathology | Microfluidics - methods | Medical research | Semiconductors | Oncology | Medical diagnosis | Cells | Blood | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
by Kristin Bergethon and Alice T. Shaw and Sai-Hong Ignatius Ou and Ryohei Katayama and Christine M. Lovly and Nerina T. McDonald and Pierre P. Massion and Christina Siwak-Tapp and Adriana Gonzalez and Rong Fang and Eugene J. Mark and Julie M. Batten and Haiquan Chen and Keith D. Wilner and Eunice L. Kwak and Jeffrey W. Clark and David P. Carbone and Hongbin Ji and Jeffrey A. Engelman and Mari Mino-Kenudson and William Pao and A. John Iafrate
Journal of clinical oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 8, pp. 863 - 870
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Screening Assays, Antitumor | Index Medicus | Original Reports | Thor9 | Thor2 | Thor12
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
by Alice T. Shaw and Beow Y. Yeap and Mari Mino-Kenudson and Subba R. Digumarthy and Daniel B. Costa and Rebecca S. Heist and Benjamin Solomon and Hannah Stubbs and Sonal Admane and Ultan McDermott and Jeffrey Settleman and Susumu Kobayashi and Eugene J. Mark and Scott J. Rodig and Lucian R. Chirieac and Eunice L. Kwak and Thomas J. Lynch and A. John Iafrate
Journal of clinical oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 26, pp. 4247 - 4253
Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Erlotinib Hydrochloride | Immunohistochemistry | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Oncogene Proteins, Fusion - metabolism | Age Factors | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein-Tyrosine Kinases - genetics | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Genes, ras - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Genotype | In Situ Hybridization, Fluorescence | Treatment Outcome | Receptor Protein-Tyrosine Kinases | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Sex Factors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Index Medicus | Original Reports | Thoracic Oncology | Thor12 | To8 | To20
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
by Zhu, Andrew X, Dr and Meyerhardt, Jeffrey A, MD and Blaszkowsky, Lawrence S, MD and Kambadakone, Avinash R, MD and Muzikansky, Alona, MS and Zheng, Hui, PhD and Clark, Jeffrey W, MD and Abrams, Thomas A, MD and Chan, Jennifer A, MD and Enzinger, Peter C, MD and Bhargava, Pankaj, MD and Kwak, Eunice L, MD and Allen, Jill N, MD and Jain, Sanjay R, MD and Stuart, Keith, MD and Horgan, Kerry, BA and Sheehan, Susan, RN and Fuchs, Charles S, MD and Ryan, David P, MD and Sahani, Dushyant V, MD
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 48 - 54
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Positron-Emission Tomography | Biliary Tract Neoplasms - mortality | Bevacizumab | Antibodies, Monoclonal, Humanized | Deoxycytidine - therapeutic use | Time Factors | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Biliary Tract Neoplasms - diagnostic imaging | Adult | Deoxycytidine - adverse effects | Female | Biliary Tract Neoplasms - drug therapy | Radiopharmaceuticals | Angiogenesis Inhibitors - adverse effects | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18 | Aged | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
by Jochen K. Lennerz and Eunice L. Kwak and Allison Ackerman and Michael Michael and Stephen B. Fox and Kristin Bergethon and Gregory Y. Lauwers and James G. Christensen and Keith D. Wilner and Daniel A. Haber and Ravi Salgia and Yung-Jue Bang and Jeffrey W. Clark and Benjamin J. Solomon and A. John Iafrate
Journal of clinical oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 36, pp. 4803 - 4810
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Receptor, Epidermal Growth Factor - genetics | Pyrazoles - therapeutic use | Adenocarcinoma - pathology | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Esophageal Neoplasms - pathology | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Pyridines - therapeutic use | Stomach Neoplasms - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Proto-Oncogene Proteins c-met - genetics | Gene Amplification | Esophageal Neoplasms - genetics | Genes, erbB-2 | Protein Kinase Inhibitors - therapeutic use | Aged | Esophageal Neoplasms - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gic9 | Gic37 | Gic14 | Gic42
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights